Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:AKTX NASDAQ:CPIX NASDAQ:RGLS NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.24$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$10.94$9.01$3.02▼$49.60$12.53M1.332.33 million shs67,595 shsCPIXCumberland Pharmaceuticals$5.72$4.76$1.85▼$6.61$85.69M0.0990,109 shs40,382 shsRGLSRegulus Therapeutics$8.16$8.10$2.22▼$8.35$564.92M0.352.68 million shsN/ASNGXSoligenix$0.40$0.68$0.28▼$6.23$5.92M1.8420.98 million shs857,268 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%0.00%0.00%-13.68%AKTXAkari Therapeutics-8.83%-26.18%+203.22%+110.22%-76.22%CPIXCumberland Pharmaceuticals+1.96%+0.88%+5.73%+102.12%+6.72%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%-0.61%SNGXSoligenix-0.62%-7.31%+6.36%-66.71%-77.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.24$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$10.94$9.01$3.02▼$49.60$12.53M1.332.33 million shs67,595 shsCPIXCumberland Pharmaceuticals$5.72$4.76$1.85▼$6.61$85.69M0.0990,109 shs40,382 shsRGLSRegulus Therapeutics$8.16$8.10$2.22▼$8.35$564.92M0.352.68 million shsN/ASNGXSoligenix$0.40$0.68$0.28▼$6.23$5.92M1.8420.98 million shs857,268 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%0.00%0.00%-13.68%AKTXAkari Therapeutics-8.83%-26.18%+203.22%+110.22%-76.22%CPIXCumberland Pharmaceuticals+1.96%+0.88%+5.73%+102.12%+6.72%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%-0.61%SNGXSoligenix-0.62%-7.31%+6.36%-66.71%-77.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AAKTXAkari Therapeutics 2.25Hold$89.00713.53% UpsideCPIXCumberland Pharmaceuticals 1.00SellN/AN/ARGLSRegulus Therapeutics 0.00N/AN/AN/ASNGXSoligenix 2.00Hold$6.001,401.88% UpsideCurrent Analyst Ratings BreakdownLatest AEZS, RGLS, CPIX, AKTX, and SNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SNGXSoligenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2026AKTXAkari Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.003/27/2026CPIXCumberland Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.33N/AN/A$14.99 per share0.21AKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/ACPIXCumberland Pharmaceuticals$44.52M1.92$0.37 per share15.30$1.64 per share3.49RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ASNGXSoligenix$120K49.34N/AN/A$0.52 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/AN/AN/A-760.32%-83.45%-45.76%N/AAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-123.29%-63.01%8/18/2026 (Estimated)CPIXCumberland Pharmaceuticals-$2.84M-$0.49N/AN/AN/A-17.60%-12.01%-4.24%8/11/2026 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/ASNGXSoligenix-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)Latest AEZS, RGLS, CPIX, AKTX, and SNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026AKTXAkari Therapeutics-$1.33-$688.00-$686.67N/AN/AN/A5/8/2026Q1 2026SNGXSoligenix-$0.30-$0.28+$0.02-$0.28N/AN/A5/5/2026Q1 2026CPIXCumberland Pharmaceuticals-$0.13-$0.13N/A-$0.22$8.50 million$9.13 million3/30/2026Q4 2025AKTXAkari Therapeutics-$0.03-$2.68-$2.65-$2.6650N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93AKTXAkari TherapeuticsN/A0.270.27CPIXCumberland Pharmaceuticals0.250.950.79RGLSRegulus TherapeuticsN/A16.3116.31SNGXSoligenixN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%AKTXAkari Therapeutics5.06%CPIXCumberland Pharmaceuticals15.51%RGLSRegulus Therapeutics92.38%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%AKTXAkari Therapeutics32.20%CPIXCumberland Pharmaceuticals42.07%RGLSRegulus Therapeutics4.35%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataAKTXAkari Therapeutics91.15 million776,000Not OptionableCPIXCumberland Pharmaceuticals8014.98 million8.68 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableSNGXSoligenix2014.82 million14.37 millionNot OptionableAEZS, RGLS, CPIX, AKTX, and SNGX HeadlinesRecent News About These CompaniesSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineJune 8, 2026 | prnewswire.comSoligenix Expands At-The-Market Equity Financing CapacityMay 28, 2026 | tipranks.comSNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail FrenzyMay 27, 2026 | finance.yahoo.comSuitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoMay 26, 2026 | prnewswire.comSOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deSoligenix Announces Recent Updates and First Quarter 2026 Financial ResultsMay 8, 2026 | prnewswire.comSNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatmentApril 29, 2026 | msn.comSNGX phase 3 trial halted on HyBryteApril 29, 2026 | msn.comSOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | finanznachrichten.deSNGX phase 3 trial halted — HyBryte setback puts strategy in questionApril 28, 2026 | msn.comSoligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaApril 28, 2026 | prnewswire.comSoligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachApril 23, 2026 | usatoday.comSoligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | financial-news.co.ukSoligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusApril 20, 2026 | finance.yahoo.comSoligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study ResultsApril 17, 2026 | financial-news.co.ukSoligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsApril 17, 2026 | finance.yahoo.comSoligenix (SNGX) price target decreased by 14.29% to 15.30April 15, 2026 | msn.comBIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 10, 2026 | thederrick.comTSNGX: Interim analysis for phase 3 CTCL study in 2Q26April 6, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, RGLS, CPIX, AKTX, and SNGX Company DescriptionsAeterna Zentaris NASDAQ:AEZSAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Akari Therapeutics NASDAQ:AKTX$10.94 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$10.50 -0.45 (-4.07%) As of 06/18/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cumberland Pharmaceuticals NASDAQ:CPIX$5.72 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$5.79 +0.07 (+1.21%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Soligenix NASDAQ:SNGX$0.40 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.40 +0.01 (+1.38%) As of 06/18/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
